Clinical Trial Update: A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase II study evaluating zanubrutinib in combination with four cycles of a CD20 monoclonal antibody and reduced-dose ben…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Bendamustine (Bendamustine)
• CD20 monoclonal antibody
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Waldenström Macroglobulinemia (WM) | Phase 2 | Status: NOT_YET_RECRUITING